Johnson & Johnson
JNJ · NYSE
9/28/2025 | 6/29/2025 | 3/30/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.88 | -0.33 | 0.04 | 0.92 |
| FCF Yield | 1.90% | 0.67% | 0.84% | 1.39% |
| EV / EBITDA | 46.21 | 45.95 | 26.44 | 60.92 |
| Quality | ||||
| ROIC | 3.29% | 3.85% | 3.37% | 2.50% |
| Gross Margin | 69.56% | 67.87% | 66.40% | 68.35% |
| Cash Conversion Ratio | 1.78 | 0.70 | 0.38 | 2.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.75% | 1.72% | 0.27% | -0.86% |
| Free Cash Flow Growth | 237.94% | -26.30% | -30.45% | -15.33% |
| Safety | ||||
| Net Debt / EBITDA | -1.28 | 3.68 | 0.88 | 2.12 |
| Interest Coverage | 394.22 | 22.11 | 30.88 | 28.04 |
| Efficiency | ||||
| Inventory Turnover | 0.52 | 0.57 | 0.58 | 0.57 |
| Cash Conversion Cycle | 121.78 | 114.23 | 103.95 | 102.57 |